Nimbus Puts Off IPO A While Longer With $400m From Gilead
This article was originally published in Scrip
Executive Summary
Nimbus Therapeutics LLC was considering an initial public offering to fund its early-stage development programs, but with $400m up front from Gilead Sciences Inc. from the sale of its subsidiary Nimbus Apollo Inc., the company can hold off until the market is more favorable for biotechnology IPOs.